<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "9: cannot ensure", fill: "#00a86b"},
{source: "9: cannot ensure", target: "9: clinical testing will", fill: "#00a86b"},
{source: "9: clinical testing will", target: "9: regulatory approval", fill: "#00a86b"},
{source: "9: regulatory approval", target: "9: manufacture", fill: "#00a86b"},
{source: "9: manufacture", target: "9: appropriate quantities", fill: "#00a86b"},
{source: "9: appropriate quantities", target: "9: successfully market", fill: "#00a86b"},
{source: "9: cannot ensure", target: "13: additional expenditures", fill: "#e2062c"},
{source: "13: additional expenditures", target: "13: clinical trials", fill: "#e2062c"},
{source: "13: clinical trials", target: "13: pursue regulatory", fill: "#e2062c"},
{source: "13: pursue regulatory", target: "13: manufacturing", fill: "#e2062c"},
{source: "13: manufacturing", target: "13: facilities", fill: "#e2062c"},
{source: "13: facilities", target: "13: establish marketing sales", fill: "#e2062c"},
{source: "13: establish marketing sales", target: "13: administrative", fill: "#e2062c"},
{source: "13: administrative", target: "13: capabilities", fill: "#e2062c"},
{source: "13: additional expenditures", target: "23: PolyHeme ", fill: "#967117"},
{source: "23: PolyHeme ", target: "23: acute blood loss", fill: "#967117"},
{source: "23: acute blood loss", target: "23: transfusion", fill: "#967117"},
{source: "23: PolyHeme ", target: "51: blood supplies under", fill: "#c41e3a"},
{source: "51: blood supplies under", target: "51: agreement", fill: "#c41e3a"},
{source: "51: blood supplies under", target: "START_HERE", fill: "#c41e3a"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Formally complain</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dreadnought-class_submarine">Dreadnought-class submarine</a></td>
      <td>The Dreadnought class is the future replacement for the Vanguard class of ballistic missile submarines. Like their predecessors they will carry Trident II D-5 missiles.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kundalini">Kundalini</a></td>
      <td>In Hinduism, Kundalini (Sanskrit: कुण्डलिनी, romanized: kuṇḍalinī, lit. 'coiled snake', pronunciation ) is a form of divine feminine energy (or Shakti) believed to be located at the base of the spine, in the muladhara. It is an important concept in Śhaiva Tantra, where it is believed to be a force or power associated with the divine feminine or the formless aspect of the Goddess.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Action_(philosophy)">Action (philosophy)</a></td>
      <td>An action is an event that an agent performs for a purpose, that is guided by the person's intention. The first question in the philosophy of action is to determine how actions differ from other forms of behavior, like involuntary reflexes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ground_and_neutral">Ground and neutral</a></td>
      <td>Ground and neutral are circuit conductors used in alternating current electrical systems. The ground circuit is connected to earth, and neutral circuit is usually connected to ground.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liberal_institutionalism">Liberal institutionalism</a></td>
      <td>Liberal institutionalism (or institutional liberalism or neoliberalism) is a theory of international relations that holds that international cooperation between states is feasible and sustainable, and that such cooperation can reduce conflict and competition. Neoliberalism is a revised version of liberalism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Suicide_watch">Suicide watch</a></td>
      <td>Suicide watch (sometimes shortened to SW) is an intensive monitoring process used to ensure that any person cannot attempt suicide. Usually the term is used in reference to inmates or patients in a prison, hospital, psychiatric hospital or military base.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cardiac_tamponade">Cardiac tamponade</a></td>
      <td>Cardiac tamponade, also known as pericardial tamponade (), is the buildup of fluid in the pericardium (the sac around the heart), resulting in compression of the heart. Onset may be rapid or gradual.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Insurgency">Insurgency</a></td>
      <td>An insurgency is a violent, armed rebellion against authority waged by small, lightly armed bands who practice guerrilla warfare from primarily rural base areas. The key descriptive feature of insurgency is its asymmetric nature: small irregular forces face a large, well-equipped, regular military force state adversary.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Islamic_socialism">Islamic socialism</a></td>
      <td>Islamic socialism is a political philosophy that incorporates Islamic principles into socialism. As a term, it was coined by various Muslim leaders to describe a more spiritual form of socialism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Advanced_manufacturing">Advanced manufacturing</a></td>
      <td>Advanced manufacturing is the use of innovative technology to improve products or processes, with the relevant technology being described as "advanced," "innovative," or "cutting edge." Advanced manufacturing industries "increasingly integrate new innovative technologies in both products and processes. The rate of technology adoption and the ability to use that technology to remain competitive and add value to define the advanced manufacturing sector."Engineers globally have implemented a variety of advanced technologies to improve the efficacy and efficiency of critical parts, such as parts within high temperature engines or surgical equipment, such as utilizing advanced materials and miniaturizing critical parts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Blood_substitute">Blood substitute</a></td>
      <td>A blood substitute (also called artificial blood or blood surrogate) is a substance used to mimic and fulfill some functions of biological blood. It aims to provide an alternative to blood transfusion, which is transferring blood or blood-based products from one person into another.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Northfield_Laboratories">Northfield Laboratories</a></td>
      <td>Northfield Laboratories Inc. ( former NASDAQ: NFLD ) was the maker of PolyHeme, a hemoglobin-based oxygen carrier (HBOC).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vera_Sharav">Vera Sharav</a></td>
      <td>Vera Sharav, a medical activist, is the founder of the Alliance for Human Research Protection, and an activist against some practices of the biomedical industry, particularly in matters of patient consent and children.\n\n\n== Biography ==\nSharav was born in 1937 in Romania and survived the Holocaust as a child; her father did not survive.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jehovah's_Witnesses">Jehovah's Witnesses</a></td>
      <td>Jehovah's Witnesses is a millenarian restorationist Christian denomination with nontrinitarian beliefs distinct from mainstream Christianity. The group reports a worldwide membership of approximately 8.7 million adherents involved in evangelism and an annual Memorial attendance of over 21 million.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bloodless_surgery">Bloodless surgery</a></td>
      <td>Bloodless surgery is a non-invasive surgical method developed by orthopedic surgeon, Adolf Lorenz, who was known as "the bloodless surgeon of Vienna". His medical practice was a consequence of his severe allergy to carbolic acid routinely used in operating rooms of the era.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jehovah's_Witnesses_and_blood_transfusions">Jehovah's Witnesses and blood transfusions</a></td>
      <td>Jehovah's Witnesses believe that the Bible prohibits Christians from accepting blood transfusions. Their literature states that, "'abstaining from ...</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Informed_consent">Informed consent</a></td>
      <td>Informed consent is a principle in medical ethics and medical law that a patient should have sufficient information before making their own free decisions about their medical care. A healthcare provider is often held to have a responsibility to ensure that the consent that a patient gives is informed, and informed consent can apply to a health care intervention on a person, conducting some form of research on a person, or for disclosing a person's information.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bacillus_anthracis">Bacillus anthracis</a></td>
      <td>Bacillus anthracis is a Gram-positive and rod-shaped bacterium that causes anthrax, a deadly disease to livestock and, occasionally, to humans. It is the only permanent (obligate) pathogen within the genus Bacillus.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_iron_metabolism">Human iron metabolism</a></td>
      <td>Human iron metabolism is the set of chemical reactions that maintain human homeostasis of iron at the systemic and cellular level.  Iron is both necessary to the body and potentially toxic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Iron">Iron</a></td>
      <td>Iran (Persian: ایران Irân [ʔiːˈɾɒːn] (listen)), also called Persia, and officially the Islamic Republic of Iran, is a country in Western Asia. It is bordered by Iraq and Turkey to the west, by Azerbaijan and Armenia to the northwest, by the Caspian Sea and Turkmenistan to the north, by Afghanistan and Pakistan to the east, and by the Gulf of Oman and the Persian Gulf to the south.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NORTHFIELD LABORATORIES INC /DE/      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>You  should  consider  the <font color="blue">following matters</font> when reviewing the     information contained in this document</td>
    </tr>
    <tr>
      <td>You <font color="blue">also should</font> consider the other     information <font color="blue">incorporated by reference</font> in this document</td>
    </tr>
    <tr>
      <td>We are a <font color="blue"><font color="blue"><font color="blue">development</font> stage company</font> without revenues</font> or profits</td>
    </tr>
    <tr>
      <td><font color="blue">Northfield </font>was founded in 1985 and is a <font color="blue"><font color="blue">development</font> stage company</font></td>
    </tr>
    <tr>
      <td>Since 1985, we have been engaged primarily in the <font color="blue">development</font> and clinical     testing of PolyHeme</td>
    </tr>
    <tr>
      <td>No revenues have <font color="blue">been generated</font> to <font color="blue">date from commercial</font>     sales of PolyHeme</td>
    </tr>
    <tr>
      <td>Our revenues to date have <font color="blue">consisted solely</font> of license     fees</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that our <font color="blue"><font color="blue">clinical testing</font> will</font> be successful, that     <font color="blue"><font color="blue">regulatory</font> approval</font> <font color="blue">of PolyHeme </font>will be obtained, that we will be able to     <font color="blue">manufacture</font> PolyHeme at an acceptable cost and in <font color="blue"><font color="blue">appropriate</font> quantities</font> or     that we will be able to <font color="blue"><font color="blue">successfully</font> market</font> and sell PolyHeme</td>
    </tr>
    <tr>
      <td>We also     <font color="blue">cannot ensure</font> that we will not <font color="blue">encounter unexpected <font color="blue">difficult</font>ies which will</font>     have a material adverse effect on us, our <font color="blue">operations</font> or our properties</td>
    </tr>
    <tr>
      <td>We have a history of losses and our <font color="blue">future <font color="blue">profitability</font></font> is uncertain</td>
    </tr>
    <tr>
      <td>From  our  <font color="blue">inception through</font> May 31, 2006, we have <font color="blue">incurred net</font>     operating  losses  totaling  dlra172cmam136cmam000</td>
    </tr>
    <tr>
      <td>We will require substantial     <font color="blue"><font color="blue">additional</font> <font color="blue">expenditures</font></font> to complete <font color="blue"><font color="blue">clinical trial</font>s</font>, to <font color="blue">pursue <font color="blue">regulatory</font></font>     approval for PolyHeme, to establish commercial scale <font color="blue">manufacturing</font> processes     and  <font color="blue">facilities</font>,  and to establish marketing, sales and <font color="blue">administrative</font>     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">expenditures</font> are expected to result in substantial     losses for at least the <font color="blue">next few years</font> and are expected to <font color="blue">substantially</font>     exceed our <font color="blue">currently available capital resources</font></td>
    </tr>
    <tr>
      <td>The expense and the time     required  to  realize any <font color="blue">product revenues</font> or <font color="blue">profitability</font> are highly     uncertain</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that we will be able to achieve <font color="blue">product revenues</font>     or <font color="blue">profitability</font> on a <font color="blue">sustained basis</font> or at all</td>
    </tr>
    <tr>
      <td>We  are developing a <font color="blue">single product</font> that is subject to a <font color="blue">high level</font> of     <font color="blue"><font color="blue">technological</font> risk</font></td>
    </tr>
    <tr>
      <td>To succeed as a company, we must develop PolyHeme <font color="blue">commercially</font> and     <font color="blue">sell adequate quantities</font> <font color="blue">of PolyHeme </font>at a <font color="blue">high enough price</font> to generate a     profit</td>
    </tr>
    <tr>
      <td>We may not accomplish either of these <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font>     have to <font color="blue">date consisted primarily</font> of the <font color="blue">development</font> and <font color="blue">clinical testing</font> of     PolyHeme</td>
    </tr>
    <tr>
      <td>We  do  not  expect  to  realize <font color="blue">product revenues</font> unless we     <font color="blue">successfully</font> develop and achieve <font color="blue">commercial introduction</font> of PolyHeme</td>
    </tr>
    <tr>
      <td>We     expect that <font color="blue">such revenues</font>, if any, will be <font color="blue">derived solely from sales</font> of     PolyHeme directly or <font color="blue">through licensees</font></td>
    </tr>
    <tr>
      <td>We also expect the use of <font color="blue"><font color="blue">PolyHeme  </font>   </font>initially to be limited to the <font color="blue">acute blood loss</font> segment of the <font color="blue">transfusion</font>     market</td>
    </tr>
    <tr>
      <td>The  biomedical  field  has  undergone  rapid and <font color="blue">significant</font>     <font color="blue">technological</font> changes</td>
    </tr>
    <tr>
      <td><font color="blue">Technological </font><font color="blue">development</font>s may result in <font color="blue"><font color="blue">PolyHeme  </font>   </font><font color="blue">becoming obsolete</font> or non-<font color="blue">competitive</font> before we are able to recover any     portion of the research and <font color="blue">development</font> and other expenses we have incurred     to develop and <font color="blue">clinically test</font> PolyHeme</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such occurrence would</font> have a     material adverse effect on us and our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  are  required  to receive FDA approval before we may sell <font color="blue"><font color="blue">PolyHeme  </font>   </font><font color="blue">commercially</font>, data from our <font color="blue"><font color="blue">clinical trial</font>s</font> to date may not be adequate to     obtain FDA approval, and we may be required to <font color="blue">conduct <font color="blue">additional</font> clinical</font>     trials in the future</td>
    </tr>
    <tr>
      <td>We recently completed <font color="blue">patient <font color="blue">enrollment</font></font> in a pivotal <font color="blue">Phase III </font>trial     in which PolyHeme was used for the first time to <font color="blue">treat severely injured</font>     patients before they reach the hospital</td>
    </tr>
    <tr>
      <td>We anticipate that we will require     <font color="blue">approximately</font>  <font color="blue">three months from</font> the date of the <font color="blue">completion</font> of patient     <font color="blue">enrollment</font> to monitor and lock the <font color="blue">database from</font> our pivotal <font color="blue">Phase III </font>    trial</td>
    </tr>
    <tr>
      <td>There can be     no assurance that we will be able to complete our <font color="blue">evaluation</font> of or report     the data from our pivotal <font color="blue">Phase III </font><font color="blue">trial within</font> these time periods</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>can also be no assurance that the data, once reported, will be favorable or     will  be sufficient to <font color="blue">demonstrate</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of our     PolyHeme product for purposes of obtaining FDA approval for the commercial     sale of the product in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">preparation</font> of a BLA is a     complex and time-consuming process and there can be no assurance                                         13       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font>that we will be able to submit our BLA within this time period</td>
    </tr>
    <tr>
      <td>If the     <font color="blue">completion</font> of our BLA takes <font color="blue">longer than</font> expected, FDA approval for the     <font color="blue">commercial sale</font> <font color="blue">of PolyHeme </font>may be <font color="blue">substantially</font> delayed</td>
    </tr>
    <tr>
      <td>FDA <font color="blue">previously</font>     issued an RTF to us in 2001 when we submitted a BLA <font color="blue"><font color="blue">based on</font> data from</font> our     prior <font color="blue">Phase II </font><font color="blue">trauma trials</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">recently applied</font> to <font color="blue">FDA for <font color="blue">Fast Track </font>    </font><font color="blue">designation</font> for PolyHeme</td>
    </tr>
    <tr>
      <td>We also plan to <font color="blue">seek <font color="blue">priority review</font></font> of our BLA     filing</td>
    </tr>
    <tr>
      <td>Even if FDA accepts our BLA filing, there can be no assurance that     FDA  will  grant PolyHeme <font color="blue">Fast Track </font><font color="blue">designation</font> or will grant the BLA     <font color="blue">priority review</font></td>
    </tr>
    <tr>
      <td>There can also be no assurance that FDA will determine that     the  trial data included in our BLA are sufficient to <font color="blue">demonstrate</font> that     <font color="blue">PolyHeme  </font>is  safe or that we have achieved the <font color="blue">clinical <font color="blue">endpoints</font></font> for     <font color="blue"><font color="blue">effective</font>ness</font> that are part of the <font color="blue">trial protocol</font> for our pivotal <font color="blue">Phase III </font>    trial</td>
    </tr>
    <tr>
      <td>FDA may accordingly refuse to approve PolyHeme for <font color="blue">commercial sale</font> or     may require us to conduct <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">of PolyHeme </font>in order to     obtain approval</td>
    </tr>
    <tr>
      <td>Even if FDA approval for the <font color="blue">commercial sale</font> <font color="blue">of PolyHeme </font>is     obtained, it may include <font color="blue">significant</font> <font color="blue">limitations</font> on the <font color="blue">indicated uses</font> for     which PolyHeme may be marketed</td>
    </tr>
    <tr>
      <td>FDA requires a <font color="blue">separate approval</font> for each     <font color="blue">proposed indication</font> for the use <font color="blue">of PolyHeme </font>in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If we want     to expand PolyHeme’s <font color="blue">indications</font>, we will have to design <font color="blue">additional</font> clinical     trials, submit the <font color="blue"><font color="blue">trial design</font>s</font> to FDA for review and complete those trials     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> are     <font color="blue">critically dependent on</font> receiving FDA approval of PolyHeme</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font>     delay in achieving or failure to achieve FDA approval for <font color="blue">commercial sale</font>s     <font color="blue">of PolyHeme </font>would have a material adverse effect on us and could result in     the cessation of our business</td>
    </tr>
    <tr>
      <td>There  may  be  <font color="blue">limitations</font> in the supply of the starting material for     PolyHeme</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently purchase donated red blood cells from</font> The American Red     Cross and Blood Centers of America for use as the starting material for     PolyHeme</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also entered into</font> an <font color="blue">agreement</font> with hemerica, Inc, a     subsidiary of Blood Centers of America, under which hemerica would supply us     with up to 160cmam000 units per year of packed red cells, the source material     for PolyHeme</td>
    </tr>
    <tr>
      <td>We have not purchased any <font color="blue">blood supplies under</font> this <font color="blue">agreement</font>     to date</td>
    </tr>
    <tr>
      <td>We have plans to <font color="blue">enter into</font> long-term supply arrangements with     other <font color="blue">blood collectors</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that we will be able to <font color="blue">enter into</font>     satisfactory long-term arrangements with blood bank operators, that the     price we may be required to pay for starting material <font color="blue">will permit us</font> to     price PolyHeme <font color="blue"><font color="blue">competitive</font>ly</font> or that we will be able to obtain an adequate     supply of starting material</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>demand for <font color="blue">blood may</font> arise from     competing human hemoglobin-based oxygen <font color="blue">carrier products</font>, thereby limiting     our <font color="blue">available supply</font> of starting material</td>
    </tr>
    <tr>
      <td>The <font color="blue">market may</font> not accept our product</td>
    </tr>
    <tr>
      <td>Even if PolyHeme is approved for <font color="blue">commercial sale</font> by FDA, the degree of     market <font color="blue">acceptance</font> <font color="blue">of PolyHeme </font>by physicians, healthcare professionals and     <font color="blue">third party payors</font>, and our <font color="blue">profitability</font> and <font color="blue">growth will <font color="blue">depend on</font></font> a number     of factors, including:         •  <font color="blue">relative convenience</font> and ease of <font color="blue">administration</font>;         •  the prevalence and severity of any adverse side effects;         •  <font color="blue"><font color="blue">effective</font>ness</font> of our sales and <font color="blue">marketing strategy</font>; and         •  the price <font color="blue">of PolyHeme </font><font color="blue">compared with</font> other hemoglobin-based oxygen     <font color="blue">carrier products</font></td>
    </tr>
    <tr>
      <td>In addition, even if PolyHeme does achieve market <font color="blue">acceptance</font>, we may     not be able to maintain that market <font color="blue">acceptance</font> over time if <font color="blue">new products</font> are     introduced that are more favorably received than PolyHeme or render <font color="blue"><font color="blue">PolyHeme  </font>   </font>obsolete</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>We <font color="blue">rely on <font color="blue">third parties</font></font> to coordinate our <font color="blue"><font color="blue">clinical trial</font>s</font> and perform data     <font color="blue">collection</font> and analysis, which may result in costs and delays that prevent     us from <font color="blue">successfully</font> <font color="blue">commercializing</font> our product</td>
    </tr>
    <tr>
      <td>We  do  not  have  the  ability  to conduct our <font color="blue"><font color="blue">clinical trial</font>s</font>     <font color="blue"><font color="blue">independent</font>ly</font></td>
    </tr>
    <tr>
      <td>We rely and <font color="blue">will continue</font> to <font color="blue">rely on clinical investigators</font>,     third-party clinical research <font color="blue">organizations</font> and <font color="blue">consultants</font> to perform some     of the functions <font color="blue">associated with</font> <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Our BLA may be delayed, suspended or terminated if:         •  these <font color="blue">third parties</font> do not <font color="blue">successfully</font> carry out their <font color="blue">contractual</font>     duties or <font color="blue"><font color="blue">regulatory</font> obligations</font> or meet expected <font color="blue">deadlines</font>;         •  these <font color="blue">third parties</font> need to be replaced; or          •  the quality or accuracy of the data obtained by <font color="blue">third parties</font> is     <font color="blue">compromised due</font> to their failure to adhere to our <font color="blue">clinical protocol</font> or     <font color="blue"><font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></font> or for other reasons</td>
    </tr>
    <tr>
      <td>Failure to perform by these <font color="blue">third parties</font> may increase our <font color="blue">development</font>     costs, delay our ability to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> and prevent the     <font color="blue">commercialization</font> of our product</td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font> are and <font color="blue">will continue</font> to be subject to extensive <font color="blue">government</font>     regulation</td>
    </tr>
    <tr>
      <td>Our research, <font color="blue">development</font>, testing, <font color="blue">manufacturing</font>, marketing and     <font color="blue">distribution</font> <font color="blue">of PolyHeme </font>are, and <font color="blue">will continue</font> to be, subject to extensive     regulation, monitoring and <font color="blue">approval by</font> FDA The <font color="blue"><font color="blue">regulatory</font> approval</font> process     to establish the safety and <font color="blue"><font color="blue">effective</font>ness</font> <font color="blue">of PolyHeme </font>and the safety and     <font color="blue">reliability</font> of our <font color="blue">manufacturing</font> process has <font color="blue">already consumed</font> considerable     time and <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">taken advantage</font> of Special Protocol Assessment, or SPA, one of     the  features  of the <font color="blue">Food and Drug Modernization Act </font>of 1997</td>
    </tr>
    <tr>
      <td><font color="blue">Our SPA     </font>reflects an <font color="blue">agreement</font> with FDA on our <font color="blue">trial design</font>, the <font color="blue">trial <font color="blue">endpoints</font></font> and     the <font color="blue">broad concepts</font> for clinical <font color="blue">indications</font> those <font color="blue"><font color="blue">endpoints</font> would support</font> in     an <font color="blue">application</font> for product <font color="blue">approval by</font> FDA The <font color="blue">assessment</font> of efficacy in     our trial will be <font color="blue">based on</font> the data on patient survival at 30 days</td>
    </tr>
    <tr>
      <td>A key     feature of our SPA is the <font color="blue">agreement</font> on dual primary <font color="blue">endpoints</font> of <font color="blue">superiority</font>     and non-inferiority between the treatment and <font color="blue">control groups</font></td>
    </tr>
    <tr>
      <td>Either of     these  <font color="blue">endpoints</font>  may be used to provide evidence of efficacy</td>
    </tr>
    <tr>
      <td><font color="blue">The SPA     </font><font color="blue">agreement</font>,  however,  is not a guarantee of product <font color="blue">approval by</font> FDA or     approval of any permissible claims about the product</td>
    </tr>
    <tr>
      <td>In particular, it is     not <font color="blue">binding on</font> the FDA if <font color="blue">previously</font> unrecognized public health concerns     <font color="blue">later comes</font> to light, other <font color="blue">new scientific concerns</font> regarding <font color="blue">product safety</font>     or efficacy arise, the <font color="blue">sponsor fails</font> to <font color="blue">comply with</font> the <font color="blue">protocol agreed</font>     upon, or FDA’s reliance on data, assumptions or information are determined     to be wrong</td>
    </tr>
    <tr>
      <td>Even after an SPA <font color="blue">agreement</font> is finalized, the SPA <font color="blue">agreement</font> may     be changed by the <font color="blue">sponsor company</font> or the FDA on written <font color="blue">agreement</font> of both     parties,  and  the  FDA retains <font color="blue">significant</font> latitude and <font color="blue">discretion</font> in     <font color="blue">interpreting</font> the terms of the SPA <font color="blue">agreement</font> and the data and results from     any study that is the subject of the SPA <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In addition, the data obtained from <font color="blue"><font color="blue">clinical trial</font>s</font> are susceptible to     varying interpretations, which could delay, limit or prevent FDA <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">demonstrate</font> evidence of efficacy, our data may not     <font color="blue">demonstrate</font> safety</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that, even after extensive clinical     trials, <font color="blue"><font color="blue">regulatory</font> approval</font> will ever be obtained for PolyHeme</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">PolyHeme  </font>   </font>is approved, it would be the first hemoglobin-based oxygen carrier for human     use to receive FDA approval</td>
    </tr>
    <tr>
      <td>We will be required to submit a Biologics License Application, or BLA,     with FDA in order to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for the <font color="blue">commercial sale</font> of     PolyHeme in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Under FDA </font><font color="blue">guidelines</font>, FDA <font color="blue">may comment upon</font>     the  <font color="blue">acceptability</font>  of  a BLA following its submission</td>
    </tr>
    <tr>
      <td><font color="blue">After a BLA </font>is     <font color="blue">submitted there</font> is an initial review by FDA to be sure that all of the     required elements are included in the submission</td>
    </tr>
    <tr>
      <td>There can be no assurance     that the <font color="blue">submission will</font> be accepted for filing or that FDA may not issue a     refusal to file, or <font color="blue">RTF If an RTF </font>is issued, there is <font color="blue">opportunity</font> for     <font color="blue">dialogue between</font> the sponsor and FDA in an effort to resolve all concerns</td>
    </tr>
    <tr>
      <td>There can be no assurance that such a <font color="blue">dialogue will</font> be successful in leading     to the filing of the BLA We received an RTF from <font color="blue">FDA in November </font>2001 in     <font color="blue"><font color="blue">connection</font> with</font> our submission of a BLA <font color="blue">seeking approval</font> to market <font color="blue"><font color="blue">PolyHeme  </font>   </font>for use in the treatment of urgent, life-threatening blood loss <font color="blue">based on</font>     <font color="blue">data from patients</font> in the <font color="blue">hospital setting only</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">subsequent dialogue</font>     with FDA resulted in the mutual                                         15       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>decision  to  proceed  with  our pivotal <font color="blue">Phase III </font>trial</td>
    </tr>
    <tr>
      <td>If a new BLA     submission is filed, the timing of the FDA <font color="blue">review process</font> is uncertain and     there  can be no assurance that the full <font color="blue">review will</font> result in product     approval</td>
    </tr>
    <tr>
      <td>Moreover, if <font color="blue"><font color="blue">regulatory</font> approval</font> <font color="blue">of PolyHeme </font>is granted, the     <font color="blue">approval may</font> include <font color="blue">limitations</font> on the <font color="blue">indicated uses</font> for which <font color="blue"><font color="blue">PolyHeme  </font>   </font>may be marketed</td>
    </tr>
    <tr>
      <td>Further <font color="blue"><font color="blue">clinical trial</font>s</font> will likely be required to gain     approval to promote the use <font color="blue">of PolyHeme </font>for any <font color="blue">additional</font> <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue">discovery</font> of <font color="blue">previously</font> unknown problems with PolyHeme or     <font color="blue">unanticipated</font> problems with our <font color="blue">manufacturing</font> <font color="blue">facilities</font>, even after FDA     approval <font color="blue">of PolyHeme </font>for <font color="blue">commercial sale</font>, may result in the imposition of     <font color="blue">significant</font> restrictions, including withdrawal <font color="blue">of PolyHeme </font>from the market     or restrictions on approved <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>laws and <font color="blue">regulations</font> may     also  be  enacted  <font color="blue">which <font color="blue">could prevent</font></font> or delay <font color="blue"><font color="blue">regulatory</font> approval</font> of     PolyHeme,  including  laws  or  <font color="blue">regulations</font>  relating  to the price or     cost-<font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">medical products</font></td>
    </tr>
    <tr>
      <td>Other laws and <font color="blue">regulations</font> may be     enacted that could require us to <font color="blue">comply with</font> post-marketing <font color="blue"><font color="blue">requirement</font>s</font> for     PolyHeme that may be time-consuming and expensive</td>
    </tr>
    <tr>
      <td>Any delay or failure to     achieve <font color="blue"><font color="blue">regulatory</font> approval</font> of <font color="blue">commercial sale</font>s <font color="blue">of PolyHeme </font>or to maintain     <font color="blue"><font color="blue">compliance with</font> current</font> or <font color="blue">future laws</font> and <font color="blue">regulations</font> is likely to have a     material adverse effect on our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>FDA continues to <font color="blue">monitor products even</font> after they receive approval</td>
    </tr>
    <tr>
      <td>If     and  when FDA approves PolyHeme, its <font color="blue">manufacture</font> and <font color="blue">marketing will</font> be     subject  to <font color="blue">ongoing regulation</font>, including <font color="blue"><font color="blue">compliance with</font> current</font> good     <font color="blue">manufacturing</font> practices, adverse event reporting <font color="blue"><font color="blue">requirement</font>s</font> and FDA’s     general  <font color="blue">prohibitions</font>  against  promoting  products  for unapproved or     “off-label” uses</td>
    </tr>
    <tr>
      <td>We are also subject to inspection and <font color="blue">market surveillance</font>     by FDA for <font color="blue">compliance with</font> these and other <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">enforcement</font>     action resulting from failure, even by inadvertence, to <font color="blue">comply with</font> these     <font color="blue"><font color="blue">requirement</font>s</font> could affect the <font color="blue">manufacture</font> and marketing of PolyHeme</td>
    </tr>
    <tr>
      <td>In     addition, FDA <font color="blue">could withdraw</font> a <font color="blue">previously</font> approved product from the market     <font color="blue">upon receipt</font> of <font color="blue">newly discovered</font> information</td>
    </tr>
    <tr>
      <td>FDA <font color="blue">could also</font> require us to     conduct <font color="blue">additional</font>, and potentially expensive, studies in <font color="blue">areas outside</font> our     approved <font color="blue">indicated uses</font></td>
    </tr>
    <tr>
      <td>The  lack of <font color="blue">established criteria</font> for evaluating the safety and     <font color="blue"><font color="blue">effective</font>ness</font> of hemoglobin-based oxygen-carrying products <font color="blue">could also</font> delay     or prevent FDA approval</td>
    </tr>
    <tr>
      <td>In October 2004, FDA published for comment a draft     <font color="blue">guidance document indicating</font> suggested criteria for testing the safety and     efficacy of <font color="blue">oxygen <font color="blue">therapeutic</font>s as substitutes</font> for <font color="blue">human red blood cells</font> and     <font color="blue">providing guidance on</font> the design of <font color="blue"><font color="blue">clinical trial</font>s</font> to assess the risks and     benefits  <font color="blue">associated with</font> the use of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">draft guidance</font>     document  was  based  in  part  on  a  conference  on hemoglobin-based     oxygen-carrying products convened at <font color="blue">National Institutes of Health </font>in 1999</td>
    </tr>
    <tr>
      <td>The <font color="blue">draft guidance</font> will not be finalized and implemented until <font color="blue">completion</font> of     a <font color="blue">public comment process</font></td>
    </tr>
    <tr>
      <td>We cannot be certain when the <font color="blue">definitive guidance</font>     will be issued by FDA or what effect, if any, the <font color="blue">definitive guidance</font> may     have  on  our  <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>It is possible that, as a result of the     <font color="blue">definitive guidance</font>, we may be required to undertake <font color="blue">additional</font> pre-clinical     or <font color="blue"><font color="blue">clinical trial</font>s</font> or modify the way data from our trial are analyzed or     presented</td>
    </tr>
    <tr>
      <td>FDA’s <font color="blue">definitive guidance</font> relating to the <font color="blue">evaluation</font> of the     <font color="blue"><font color="blue">effective</font>ness</font> of hemoglobin-based oxygen-carrying products could delay or     prevent FDA <font color="blue"><font color="blue">regulatory</font> approval</font> of PolyHeme</td>
    </tr>
    <tr>
      <td>In addition, delay or rejection     could be caused by other future changes in FDA policies and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We have submitted an <font color="blue">application</font> for <font color="blue">Fast Track </font><font color="blue">designation</font> to FDA and     plan  to <font color="blue">seek <font color="blue">priority review</font></font> of PolyHeme</td>
    </tr>
    <tr>
      <td>Products awarded <font color="blue">Fast Track </font>    <font color="blue">designation</font> are eligible for more <font color="blue">frequent meetings with</font> the agency to     discuss the drug’s <font color="blue">development</font> plan, approval <font color="blue">based on</font> <font color="blue">endpoints</font> reasonably     likely to <font color="blue">predict clinical benefit</font>, and <font color="blue">rolling review</font> of the product’s     <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that FDA will award PolyHeme <font color="blue">Fast Track </font>    <font color="blue">designation</font></td>
    </tr>
    <tr>
      <td>Award of the <font color="blue">designation</font> does not ensure product <font color="blue">approval by</font>     the agency</td>
    </tr>
    <tr>
      <td>A BLA in a <font color="blue">Fast Track </font>drug <font color="blue">development</font> program ordinarily will     be eligible for “<font color="blue">priority review</font>” by FDA, although the law does not require     it</td>
    </tr>
    <tr>
      <td>Products awarded <font color="blue">priority review</font> are <font color="blue">given abbreviated review goals by</font>     the agency</td>
    </tr>
    <tr>
      <td>Priority review is <font color="blue">requested at</font> the time the BLA is submitted</td>
    </tr>
    <tr>
      <td>FDA makes a <font color="blue">decision as</font> part of the agency’s review of the <font color="blue">application</font> for     filing</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that the <font color="blue">agency will give</font> PolyHeme priority     review and <font color="blue">cannot predict</font> if awarded, what impact, if any, it will have on     the review time for PolyHeme</td>
    </tr>
    <tr>
      <td>Priority review does not ensure that FDA will     <font color="blue">ultimately approve</font> PolyHeme</td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>We expect to need to raise <font color="blue">additional</font> capital in the future to continue our     business</td>
    </tr>
    <tr>
      <td>We  expect to need to raise <font color="blue">additional</font> capital in the future to     continue our business</td>
    </tr>
    <tr>
      <td>Our future capital <font color="blue"><font color="blue">requirement</font>s</font> will <font color="blue">depend on</font> many     factors, including the scope and results of our <font color="blue"><font color="blue">clinical trial</font>s</font>, the timing     and outcome of <font color="blue">regulatory</font> reviews, <font color="blue">administrative</font> and <font color="blue">legal expenses</font>, the     status of <font color="blue"><font color="blue">competitive</font> products</font>, the <font color="blue">establishment</font> of <font color="blue">manufacturing</font> <font color="blue">capacity</font>     and the <font color="blue">establishment</font> of <font color="blue">collaborative relationships</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that     <font color="blue">additional</font> funding will be available or, if it is available, that it can be     obtained on terms and <font color="blue">conditions</font> we will deem acceptable</td>
    </tr>
    <tr>
      <td>We expect to file     a <font color="blue">shelf registration statement with</font> the SEC in the future to allow us the     <font color="blue">flexibility</font> to raise <font color="blue">additional</font> capital when we believe it is <font color="blue">appropriate</font> to     do so</td>
    </tr>
    <tr>
      <td>Any <font color="blue">additional</font> funding derived from the sale of <font color="blue">equity securities may</font>     result in <font color="blue">significant</font> dilution to our <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>In addition, we     are subject to a putative class <font color="blue">action lawsuit</font> alleging violations of the     <font color="blue">federal securities laws</font> and we also have received <font color="blue">separate requests from</font>     both the <font color="blue">SEC and the Senate <font color="blue">Committee </font></font>on Finance <font color="blue">asking us voluntarily</font> to     <font color="blue">provide certain</font> information</td>
    </tr>
    <tr>
      <td>These <font color="blue">matters involve risks</font> and <font color="blue">uncertainties</font>     that may prevent <font color="blue">Northfield </font>from raising <font color="blue">additional</font> capital or may cause the     <font color="blue">terms upon which</font> <font color="blue">Northfield </font>raises <font color="blue">additional</font> capital, if <font color="blue">additional</font> capital     is available, to be less favorable to <font color="blue">Northfield </font><font color="blue">than would otherwise</font> be the     case</td>
    </tr>
    <tr>
      <td>We currently <font color="blue">manufacture</font> PolyHeme at a <font color="blue">single location</font> and, if we were     unable to utilize this <font color="blue">facility</font>, our ability to <font color="blue">manufacture</font> PolyHeme will be     <font color="blue">significant</font>ly  affected,  and  we  will  be  delayed or <font color="blue">prevented from</font>     <font color="blue">commercializing</font> PolyHeme</td>
    </tr>
    <tr>
      <td>We currently <font color="blue">manufacture</font> PolyHeme at a <font color="blue">single location</font> and we have no     <font color="blue">alternative</font>  <font color="blue">manufacturing</font>  <font color="blue">capacity</font> in place at this time</td>
    </tr>
    <tr>
      <td>We plan to     construct  our  initial commercial <font color="blue">manufacturing</font> <font color="blue">facility</font> at this same     location</td>
    </tr>
    <tr>
      <td>Damage to this <font color="blue">manufacturing</font> <font color="blue">facility</font> due to fire, <font color="blue">contamination</font>,     natural disaster, power loss, <font color="blue">unauthorized</font> entry or other <font color="blue">events could force</font>     us to cease the <font color="blue">manufacturing</font> of PolyHeme</td>
    </tr>
    <tr>
      <td>Any lack of <font color="blue">supply could</font>, in     turn,  delay our <font color="blue">clinical trial</font> and any potential <font color="blue">commercial sale</font>s</td>
    </tr>
    <tr>
      <td>In     addition, if the <font color="blue">facility</font> or the equipment in the <font color="blue">facility</font> is <font color="blue">significant</font>ly     damaged or destroyed for any reason, we may not be able to replace our     <font color="blue">manufacturing</font> <font color="blue">capacity</font> for an <font color="blue">extended period</font> of time, and our business,     financial  condition  and results of <font color="blue">operations</font> will be <font color="blue">materially</font> and     <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>We intend to seek FDA approval of this <font color="blue">facility</font> for the     <font color="blue">commercial production</font> <font color="blue">of PolyHeme </font>if and when <font color="blue">marketing approval</font> of <font color="blue"><font color="blue">PolyHeme  </font>   </font>is obtained</td>
    </tr>
    <tr>
      <td>This <font color="blue">facility</font> will be subject to FDA <font color="blue">inspections</font> and extensive     regulation, including <font color="blue"><font color="blue">compliance with</font> current</font> good <font color="blue">manufacturing</font> practices     and FDA approval</td>
    </tr>
    <tr>
      <td>Failure to comply may result in <font color="blue">enforcement</font> action, which     may <font color="blue">significant</font>ly delay or suspend <font color="blue">manufacturing</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Failure to increase <font color="blue">manufacturing</font> <font color="blue">capacity</font> may impair PolyHeme’s market     <font color="blue">acceptance</font> and <font color="blue">prevent us from</font> achieving <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Currently,  we  have  a <font color="blue">manufacturing</font> <font color="blue">capacity</font> of <font color="blue">approximately</font>     10cmam000 units  of  <font color="blue">PolyHeme  </font>per  year  in  our current pilot <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Commercial-scale <font color="blue">manufacturing</font> <font color="blue">of PolyHeme </font>will require the <font color="blue">construction</font> of     a <font color="blue">manufacturing</font> <font color="blue">facility</font> <font color="blue">significant</font>ly larger than that currently being used     to produce PolyHeme for our <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>A commercial-scale <font color="blue">manufacturing</font>     <font color="blue">facility</font>  will be subject to FDA <font color="blue">inspections</font> and extensive regulation,     including <font color="blue"><font color="blue">compliance with</font> current</font> good <font color="blue">manufacturing</font> practices and FDA     approval of scale-up changes</td>
    </tr>
    <tr>
      <td>Failure to comply may result in <font color="blue">enforcement</font>     action, which may <font color="blue">significant</font>ly delay or suspend <font color="blue">manufacturing</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have no experience in large-scale <font color="blue">manufacturing</font>, and there can be no     assurance that we can achieve large-scale <font color="blue">manufacturing</font> <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>It is also     possible that we may incur substantial <font color="blue">cost overruns</font> and <font color="blue">delays compared</font> to     existing estimates in building and equipping a large-scale <font color="blue">manufacturing</font>     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Moreover, in order to seek FDA approval of the sale of <font color="blue"><font color="blue">PolyHeme  </font>   </font>produced at a larger-scale <font color="blue">manufacturing</font> <font color="blue">facility</font>, we may be required to     conduct <font color="blue">additional</font> studies with product <font color="blue">manufacture</font>d at that <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>A     <font color="blue">significant</font>  delay  in  achieving scale-up of commercial <font color="blue">manufacturing</font>     <font color="blue">capabilities</font> would have a material adverse effect on sales of PolyHeme</td>
    </tr>
    <tr>
      <td>There are <font color="blue">significant</font> <font color="blue">competitors</font> developing similar products</td>
    </tr>
    <tr>
      <td>We may be unable to compete <font color="blue">successfully</font> in developing and marketing     our product</td>
    </tr>
    <tr>
      <td>If approved for <font color="blue">commercial sale</font>, PolyHeme <font color="blue">will compete directly</font>     <font color="blue">with <font color="blue">established therapies</font></font> for <font color="blue">acute blood loss</font> and <font color="blue">may compete with</font> other     <font color="blue">technologies</font> currently under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that <font color="blue"><font color="blue">PolyHeme  </font>   </font>will have                                         17       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">advantages</font> which will</font> be <font color="blue">significant</font> enough to cause <font color="blue">medical professionals</font>     to adopt it <font color="blue">rather than continue</font> to <font color="blue">use <font color="blue">established therapies</font></font> or to adopt     other <font color="blue">new <font color="blue">technologies</font></font> or products</td>
    </tr>
    <tr>
      <td>We also <font color="blue">cannot ensure</font> that the cost of     PolyHeme will be <font color="blue"><font color="blue">competitive</font> with</font> the cost of <font color="blue">established therapies</font> or other     new  <font color="blue">technologies</font>  or  products</td>
    </tr>
    <tr>
      <td>The  <font color="blue">development</font> of hemoglobin-based     oxygen-carrying products is a <font color="blue">continuously evolving field</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>is     intense and may increase</td>
    </tr>
    <tr>
      <td>Several companies have developed or are in the     process of developing <font color="blue">technologies</font> which are, or in the <font color="blue">future may</font> be, the     basis  for <font color="blue">products which will compete with</font> PolyHeme</td>
    </tr>
    <tr>
      <td>Certain of these     companies are pursuing <font color="blue">different</font> approaches or means of accomplishing the     <font color="blue">therapeutic</font> effects sought to be achieved through the use of PolyHeme</td>
    </tr>
    <tr>
      <td><font color="blue">Some     </font>of these companies may have <font color="blue">substantially</font> greater financial resources,     larger research and <font color="blue">development</font> staffs, more extensive <font color="blue">facilities</font> and more     experience in testing, <font color="blue">manufacturing</font>, marketing and <font color="blue">distributing</font> medical     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that one or more other <font color="blue">companies will</font> not succeed     in developing <font color="blue">technologies</font> or <font color="blue">products which will become available</font> for     <font color="blue">commercial use prior</font> to PolyHeme, which will be more <font color="blue">effective</font> or less     <font color="blue">costly than</font> PolyHeme or which would otherwise render PolyHeme obsolete or     non-<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We do not have experience in the sale and marketing of <font color="blue">medical products</font></td>
    </tr>
    <tr>
      <td>If  approved for <font color="blue">commercial sale</font>, we <font color="blue">currently intend</font> to market     <font color="blue">PolyHeme  </font>in  the  <font color="blue">United States</font> using our own <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>We have no     experience in the sale or marketing of <font color="blue">medical products</font></td>
    </tr>
    <tr>
      <td>Our ability to     implement our sales and <font color="blue">marketing strategy</font> for the <font color="blue">United States</font> will depend     on our ability to recruit, train and retain a <font color="blue">marketing staff</font> and sales     <font color="blue">force with sufficient technical expertise</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that we will be     able to establish an <font color="blue">effective</font> <font color="blue">marketing staff</font> and <font color="blue">sales force</font>, that the     cost of <font color="blue">establishing such</font> a <font color="blue">marketing staff</font> and <font color="blue">sales force</font> will not exceed     <font color="blue">revenues from</font> the sale <font color="blue">of PolyHeme </font>or that our marketing and sales efforts     will be successful</td>
    </tr>
    <tr>
      <td>Our <font color="blue">profitability</font> will be affected if we incur <font color="blue">product liability</font> claims in     excess of our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>The  testing  and marketing of <font color="blue">medical products</font>, even after FDA     approval, have an <font color="blue">inherent risk</font> of <font color="blue">product liability</font></td>
    </tr>
    <tr>
      <td>Claims by users of     PolyHeme, or by others selling PolyHeme, <font color="blue">could expose us</font> to substantial     <font color="blue">product liability</font></td>
    </tr>
    <tr>
      <td>We maintain limited <font color="blue">product liability</font> <font color="blue">insurance coverage</font>     for our <font color="blue"><font color="blue">clinical trial</font>s</font> in the <font color="blue">total amount</font> of dlra10 million</td>
    </tr>
    <tr>
      <td>However, our     <font color="blue">profitability</font> would be <font color="blue">adversely affected</font> by a successful <font color="blue">product liability</font>     claim in excess of our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that product     <font color="blue">liability <font color="blue">insurance will</font></font> be available in the future or be <font color="blue">available on</font>     <font color="blue">reasonable terms</font></td>
    </tr>
    <tr>
      <td>Our pivotal <font color="blue">Phase III </font>trial was conducted under a <font color="blue">federal regulation</font>     that <font color="blue">allows research</font> to be conducted in certain emergent, life-threatening     <font color="blue">situations using</font> an <font color="blue">exception from</font> the <font color="blue">requirement</font> for <font color="blue">informed patient</font>     consent</td>
    </tr>
    <tr>
      <td>Under the applicable <font color="blue">federal regulation</font>, an IRB <font color="blue">may give approval</font>     for <font color="blue">patient <font color="blue">enrollment</font></font> in trials in <font color="blue">emergency situations without</font> requiring     individual <font color="blue"><font color="blue">informed consent</font> provided specific criteria</font> are met</td>
    </tr>
    <tr>
      <td><font color="blue">Individual     </font><font color="blue">informed consent</font> is often a defense raised against <font color="blue">product liability</font> claims     asserted <font color="blue"><font color="blue">by patients</font> <font color="blue">participating</font></font> in <font color="blue"><font color="blue">clinical trial</font>s</font> of <font color="blue">medical products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot ensure</font> that IRB approval of <font color="blue">patient <font color="blue">enrollment</font></font> in our trial, even     if given in full <font color="blue">compliance with</font> the applicable federal <font color="blue">regulations</font>, will     <font color="blue"><font color="blue">provide us</font> with</font> a defense against <font color="blue">product liability</font> claims <font color="blue">by patients</font>     <font color="blue">participating</font> in our trial</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that we may be subject to     legal claims <font color="blue">by patients</font> objecting to being enrolled in our trial without     their individual <font color="blue">informed consent</font>, even if the patients do not suffer any     injuries in <font color="blue"><font color="blue">connection</font> with</font> our trial</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> the services of a limited number of <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">highly dependent on</font> the <font color="blue">continued services</font> of a limited     number  of  skilled  managers and <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>The loss of any of these     <font color="blue">individuals could</font> have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>In addition, our     success will depend, among other factors, on the <font color="blue">recruitment</font> and retention     of  <font color="blue">additional</font> highly skilled and experienced <font color="blue">management</font> and technical     personnel</td>
    </tr>
    <tr>
      <td>We  cannot  ensure that we will be able to retain existing     employees  or  to  attract  and retain <font color="blue">additional</font> skilled personnel on     acceptable <font color="blue">terms given</font> the <font color="blue">competition</font> for <font color="blue">such personnel among numerous</font>     large and well-funded pharmaceutical and health care companies, universities     and non-profit research institutions</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>Our  ability  to  generate  revenue  from  our  product will <font color="blue">depend on</font>     <font color="blue">reimbursement</font> and <font color="blue">drug pricing policies</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our ability to achieve acceptable levels of <font color="blue">reimbursement</font> for <font color="blue"><font color="blue">PolyHeme  </font>   </font>by <font color="blue">government</font>al <font color="blue">authorities</font>, private health insurers and other <font color="blue">organizations</font>     will have an effect on our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> PolyHeme</td>
    </tr>
    <tr>
      <td>We  cannot  be sure that <font color="blue">reimbursement</font> in the <font color="blue">United States</font>, Europe or     elsewhere will be available <font color="blue">for PolyHeme </font>or, if <font color="blue">reimbursement</font> should become     available, that it will not be decreased or eliminated in the future</td>
    </tr>
    <tr>
      <td>If     <font color="blue">reimbursement</font> is not available or is <font color="blue">available on</font>ly at limited levels, we     may not be able to <font color="blue">successfully</font> <font color="blue">commercialize</font> PolyHeme, and may not be able     to obtain a satisfactory financial return on PolyHeme</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">payers <font color="blue">increasingly</font></font> are <font color="blue">challenging prices charged</font> for     <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>Also, the trend toward managed health care in     the <font color="blue">United States</font> and the changes in health insurance programs, as well as     <font color="blue">legislative proposals</font> to <font color="blue">reform health care</font> or reduce <font color="blue">government</font> insurance     programs, may result in <font color="blue">lower prices</font> for <font color="blue">pharmaceutical products</font>, including     PolyHeme</td>
    </tr>
    <tr>
      <td>Cost-cutting measures that <font color="blue">health care providers</font> are <font color="blue">instituting</font>,     and the effect of any health care reform, could harm our ability to sell     PolyHeme</td>
    </tr>
    <tr>
      <td>Moreover, we are unable to predict what <font color="blue">additional</font> <font color="blue">legislation</font> or     regulation, if any, relating to the <font color="blue">health care industry</font> or third-party     coverage and <font color="blue">reimbursement</font> may be enacted in the future or what effect this     <font color="blue">legislation</font> or <font color="blue">regulation would</font> have on our business</td>
    </tr>
    <tr>
      <td>In the event that     <font color="blue">government</font>al <font color="blue">authorities</font> enact <font color="blue">legislation</font> or adopt <font color="blue">regulations</font> which affect     third-party coverage and <font color="blue">reimbursement</font>, demand <font color="blue">for PolyHeme </font>may be reduced,     <font color="blue">thereby harming</font> our sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Failure to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> in foreign <font color="blue">jurisdictions</font> would prevent     our product from being marketed abroad</td>
    </tr>
    <tr>
      <td>We have entered into license <font color="blue">agreement</font>s with Pfizer Inc, formerly     known as Pharmacia Corporation, and Hemocare Ltd, an Israeli <font color="blue">corporation</font>,     to develop, <font color="blue">manufacture</font> and distribute PolyHeme in certain European, Middle     Eastern and African countries</td>
    </tr>
    <tr>
      <td>The license <font color="blue">agreement</font>s permit Pfizer and     Hemocare to sell PolyHeme in return for the payment of <font color="blue">royalties based upon</font>     sales <font color="blue">of PolyHeme </font>in the <font color="blue">licensed territories</font></td>
    </tr>
    <tr>
      <td>In order for Pfizer, Hemocare     or anyone else, including us, to market our products <font color="blue">in the European Union     </font>and  many other foreign <font color="blue">jurisdictions</font>, we or our licensees must obtain     separate  <font color="blue">regulatory</font>  approvals  and  <font color="blue">comply with</font> numerous and varying     <font color="blue"><font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">approval procedure varies among countries</font> and     can involve <font color="blue">additional</font> testing</td>
    </tr>
    <tr>
      <td>The time required to obtain <font color="blue">approval may</font>     <font color="blue">differ from</font> that required to obtain FDA approval</td>
    </tr>
    <tr>
      <td>The foreign <font color="blue">regulatory</font>     approval process entails all of the risks <font color="blue">associated with</font> obtaining FDA     approval</td>
    </tr>
    <tr>
      <td>We  and our licensees may fail to obtain foreign <font color="blue">regulatory</font>     approvals on a timely basis, if at all</td>
    </tr>
    <tr>
      <td>Approval by FDA does not ensure     <font color="blue">approval by</font> <font color="blue">regulatory</font> <font color="blue">authorities</font> in other countries, and <font color="blue">approval by</font> one     foreign  <font color="blue">regulatory</font>  authority  does not ensure <font color="blue">approval by</font> <font color="blue">regulatory</font>     <font color="blue">authorities</font> in other <font color="blue">foreign countries</font> or by FDA We and our licensees may     not be able to file for, and may not receive, <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s     to <font color="blue">commercialize</font> our product in any market</td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">licensees fail</font> to     obtain these approvals, our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>Our  financial  results  are expected to be <font color="blue">affected by</font> changes in the     <font color="blue"><font color="blue">accounting</font> rules governing</font> the <font color="blue">recognition</font> of stock-based compensation     expense</td>
    </tr>
    <tr>
      <td><font color="blue">The Financial Accounting Standards Board </font><font color="blue">recently issued</font> its <font color="blue"><font color="blue">Statement </font>    </font>of  Financial Accounting Standards Nodtta 123 (revised 2004), Share-Based     Payment (<font color="blue">Statement </font>123R), which addresses the <font color="blue">accounting</font> for <font color="blue">employee stock</font>     options</td>
    </tr>
    <tr>
      <td><font color="blue">Statement </font>123R  requires that the cost of all <font color="blue">employee stock</font>     options,  as  well as other equity-based compensation arrangements, be     reflected in financial statements <font color="blue">based on</font> the estimated <font color="blue">fair value</font> of the     awards</td>
    </tr>
    <tr>
      <td>Upon our <font color="blue">implementation</font> of <font color="blue">Statement </font>123R, we expect to be required to     recognize <font color="blue">additional</font> compensation expense</td>
    </tr>
    <tr>
      <td>Section 404 of the Sarbanes-Oxley Act of 2002 requires us to include a     report by our <font color="blue">management</font> on our <font color="blue">internal controls</font> over financial reporting     in  our annual reports filed with <font color="blue">the SEC This </font>report must contain an     <font color="blue">assessment</font> by <font color="blue">management</font> of the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal controls</font> over     financial reporting as of the end of our <font color="blue">fiscal year</font> and a <font color="blue">statement as</font> to     whether or not our <font color="blue">internal controls</font> are <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>The report must also     contain a statement that our <font color="blue"><font color="blue">independent</font> auditors</font> have issued an <font color="blue">attestation</font>     report on <font color="blue">management</font>’s <font color="blue">assessment</font> of such <font color="blue">internal controls</font></td>
    </tr>
    <tr>
      <td>Our efforts to <font color="blue">comply with</font> Section 404 have resulted in, and are     likely to continue to result in, <font color="blue">significant</font> costs, the <font color="blue">commitment</font> of time     and <font color="blue">operational resources</font> and the diversion of <font color="blue">management</font>’s attention</td>
    </tr>
    <tr>
      <td>If     our <font color="blue">management</font> identifies one or more material weaknesses in our internal     <font color="blue">controls over financial</font> reporting, we will be unable to assert our internal     controls  are  <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>If we are unable to assert that our internal     <font color="blue">controls over financial</font> reporting are <font color="blue">effective</font>, or if our <font color="blue">independent</font>     auditors are unable to attest that our <font color="blue">management</font>’s report is fairly stated     or they are unable to express an <font color="blue">opinion on</font> our <font color="blue">management</font>’s <font color="blue">evaluation</font> or     on the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal controls</font>, our business may be harmed</td>
    </tr>
    <tr>
      <td>Market <font color="blue">perception</font> of our <font color="blue">financial condition</font> and the <font color="blue">trading price</font> of our     stock may be <font color="blue">adversely affected</font> and customer <font color="blue">perception</font> of our business may     suffer</td>
    </tr>
    <tr>
      <td>We are subject to a variety of federal, state and local laws, rules and     <font color="blue">regulations</font> related to the discharge or disposal of toxic, volatile or other     <font color="blue"><font color="blue">hazardous</font> chemicals</font></td>
    </tr>
    <tr>
      <td>Although we believe that we are in material <font color="blue">compliance with</font> these     laws, rules and <font color="blue">regulations</font>, the failure to <font color="blue">comply with</font> present or future     <font color="blue">regulations</font>  could  result in fines being imposed on us, suspension of     production or cessation of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue"><font color="blue">parties may</font> also</font> have the right     to sue to <font color="blue">enforce compliance</font></td>
    </tr>
    <tr>
      <td>Moreover, it is possible that <font color="blue">increasingly</font>     strict <font color="blue"><font color="blue">requirement</font>s</font> imposed by <font color="blue">environment</font>al laws and <font color="blue">enforcement</font> policies     could require us to make <font color="blue">significant</font> capital <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>The operation of     a <font color="blue">manufacturing</font> plant entails the <font color="blue">inherent risk</font> of <font color="blue">environment</font>al damage or     personal injury due to the handling of <font color="blue">potentially harmful substances</font>, and     there  can  be  no assurance that we will not incur material costs and     <font color="blue">liabilities</font> in the future because of an <font color="blue">accident</font> or other event resulting in     personal  injury  or  <font color="blue">unauthorized</font>  release  of <font color="blue">such substances</font> to the     <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">generate <font color="blue">hazardous</font> materials</font> and other wastes     that  are disposed of at various offsite <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We may be liable,     <font color="blue">irrespective</font> of fault, for material <font color="blue">cleanup costs</font> or other <font color="blue">liabilities</font>     incurred at these disposal <font color="blue">facilities</font> in the event of a release of <font color="blue">hazardous</font>     substances by such <font color="blue">facilities</font> into the <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>We are subject to a putative class <font color="blue">action lawsuit</font> and have received requests     from both the <font color="blue">SEC and the Senate <font color="blue">Committee </font></font>on Finance <font color="blue">asking us voluntarily</font>     to provide information</td>
    </tr>
    <tr>
      <td>Steven A Gould, Northfield’s Chief Executive Officer, are     subject to a putative class <font color="blue">action pending</font> in the <font color="blue">United States</font> District     Court for the Northern District of Illinois Eastern Division, <font color="blue">purportedly</font>     <font color="blue">brought on behalf</font> of a class of Northfield’s <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>The complaint     alleges, among other things, that during the <font color="blue">period from</font> <font color="blue">December </font>22, 2003     to <font color="blue">February </font>21, 2006, the <font color="blue">named defendants</font> made or caused to be made a     series of <font color="blue">materially</font> false or <font color="blue">misleading statements</font> and <font color="blue">omissions about</font> the     Company’s  elective  surgery  <font color="blue">clinical trial</font> and business prospects in     violation  of Section 10(b) of the <font color="blue">Securities <font color="blue">Exchange Act</font> </font>of 1934, as     amended, <font color="blue">and Rule </font>10b-5 promulgated thereunder and Section 20(a) of the     <font color="blue">Exchange Act</font></td>
    </tr>
    <tr>
      <td><font color="blue">Plaintiffs </font>allege that those <font color="blue">allegedly false</font> and misleading     statements and omissions caused the purported class to purchase <font color="blue">Northfield </font>    <font color="blue"><font color="blue">common stock</font> at artificially inflated prices</font></td>
    </tr>
    <tr>
      <td>As relief, the complaint     seeks, among other things, a <font color="blue">declaration</font> that the action be <font color="blue">certified as</font> a     proper class action, unspecified compensatory damages (including interest)     and payment of costs and expenses (including fees for <font color="blue">legal counsel</font> and     experts)</td>
    </tr>
    <tr>
      <td>If the outcome of this lawsuit is unfavorable to Northfield, or     <font color="blue">Northfield </font>determines that it is advisable to <font color="blue">enter into</font> a settlement of the     lawsuit, <font color="blue">Northfield </font>could be required to pay <font color="blue">significant</font> monetary damages or     make <font color="blue">significant</font> settlement payments to the plaintiffs in the lawsuit</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [74]Table of <font color="blue">Contents       </font>      While <font color="blue">Northfield </font>maintains <font color="blue">directors</font> and <font color="blue">officers liability insurance</font>,     there  can be no assurance that the proceeds of this <font color="blue">insurance will</font> be     <font color="blue">available <font color="blue">with respect</font></font> to all or part of any damages, costs or expenses that     may be <font color="blue">incurred by</font> <font color="blue">Northfield </font>in <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">aforementioned</font> putative     class  action  lawsuit</td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">Northfield </font> is  a  party to an     indemnification <font color="blue">agreement</font> under which it may be required to indemnify and     <font color="blue">advance defense costs</font> to its current and former <font color="blue">directors</font> and officers in     <font color="blue"><font color="blue">connection</font> with</font> this putative class <font color="blue">action lawsuit</font></td>
    </tr>
    <tr>
      <td>Even if this lawsuit is     <font color="blue">ultimately resolved</font> in favor of Northfield, <font color="blue">Northfield </font><font color="blue">still may incur</font>     substantial <font color="blue">legal fees</font> and expenses in defending the lawsuit</td>
    </tr>
    <tr>
      <td>On March 13, 2006, the SEC notified <font color="blue">Northfield </font>that it is conducting     an <font color="blue">informal inquiry</font>, and requested that <font color="blue">Northfield </font><font color="blue">voluntarily provide</font> the     SEC <font color="blue">with certain categories</font> of documents from 1998 to the <font color="blue">present primarily</font>     relating  to  the company’s public <font color="blue">disclosure</font>s concerning the clinical     <font color="blue">development</font> of PolyHeme</td>
    </tr>
    <tr>
      <td><font color="blue">Northfield </font>is <font color="blue">cooperating with</font> the SEC and has been     providing the SEC with the <font color="blue">requested documents</font> and information on a rolling     basis</td>
    </tr>
    <tr>
      <td>While <font color="blue">Northfield </font>does not know and <font color="blue">cannot predict</font> the ultimate     outcome  or  future of the <font color="blue">aforementioned</font> SEC inquiry, the SEC has the     authority to pursue formal civil <font color="blue">enforcement</font> actions, civil penalties, and     <font color="blue">equitable remedies</font>, including <font color="blue">disgorgement</font> of funds and <font color="blue">injunctions against</font>     <font color="blue">future violations</font> of the <font color="blue">federal securities laws</font>, and <font color="blue">may refer criminal</font>     violations of the <font color="blue">federal securities laws</font> to the <font color="blue">United States</font> Department of     Justice for <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>On March 7, 2006, <font color="blue">Northfield </font>also received a <font color="blue">letter from</font> Senator     Charles E Grassley, Chairman of the Senate <font color="blue">Committee </font>on Finance, informing     <font color="blue">Northfield </font>that the <font color="blue">Committee </font>is concerned that Northfield’s <font color="blue">Phase III </font>    <font color="blue">clinical trauma trial may</font> not satisfy all of the criteria of the federal     regulation  that allows a waiver of <font color="blue">informed consent</font> in the context of     <font color="blue">emergency research</font></td>
    </tr>
    <tr>
      <td>While <font color="blue">Northfield </font>does not know and <font color="blue">cannot predict</font> the     <font color="blue">ultimate outcome</font> of the Committee’s investigation, actions by legislative     <font color="blue">bodies such as</font> the Senate <font color="blue">could prevent</font> or <font color="blue">materially</font> delay FDA approval of     the <font color="blue">commercial sale</font> of PolyHeme</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR INTELLECTUAL PROPERTY       Our <font color="blue"><font color="blue">success depends</font> upon</font> our ability to protect our <font color="blue">intellectual property</font>     and our <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on our ability to obtain and maintain     <font color="blue">intellectual property</font> protection <font color="blue">for PolyHeme </font>as well as our <font color="blue">technology</font> and     know-how</td>
    </tr>
    <tr>
      <td>Our policy is to seek to protect PolyHeme and our <font color="blue">technologies</font> by,     among other methods, filing <font color="blue">United States</font> and foreign patent <font color="blue">application</font>s     related to our <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font>, <font color="blue">inventions</font> and <font color="blue">improvements</font> that are     important to the <font color="blue">development</font> of PolyHeme</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of companies     like ours are <font color="blue">generally uncertain</font> and <font color="blue">involve complex legal</font> and factual     questions</td>
    </tr>
    <tr>
      <td>Our ability to maintain and solidify our <font color="blue">proprietary</font> position for     our <font color="blue">technology</font> will <font color="blue">depend on</font> our success in obtaining <font color="blue">effective</font> patent     claims and enforcing those claims <font color="blue">once granted</font></td>
    </tr>
    <tr>
      <td>We do not know whether any     of our patent <font color="blue">application</font>s will result in the issuance of any patents</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">issued patents</font> and those that may issue in the <font color="blue">future may</font> be challenged,     invalidated, rendered unenforceable or circumvented, which could limit our     ability to <font color="blue">stop <font color="blue">competitors</font> from marketing</font> related products or the length of     term of <font color="blue">patent protection</font> that we may have for PolyHeme</td>
    </tr>
    <tr>
      <td>Our <font color="blue">United States</font>     patents have <font color="blue">expiration dates</font> that extend to 2017</td>
    </tr>
    <tr>
      <td>The broadest of our     <font color="blue">issued patents</font> expires in June 2007</td>
    </tr>
    <tr>
      <td>Although we expect to be granted an     extension of this patent to 2011, we <font color="blue">cannot ensure</font> that an <font color="blue">extension will</font>     not  be for <font color="blue">less than five years</font> or that it will be <font color="blue">granted at</font> all</td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">rights granted under</font> any <font color="blue">issued patents</font> may not <font color="blue">provide us</font>     with <font color="blue">competitive</font> <font color="blue">advantages</font> against <font color="blue">competitors</font> with similar compounds or     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">competitors</font> may <font color="blue"><font color="blue">independent</font>ly</font> develop similar     <font color="blue">technologies</font> or duplicate any <font color="blue">technology</font> developed by us in a manner that     does not infringe our patents or other <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>Because of the     extensive time required for <font color="blue">development</font>, testing and <font color="blue">regulatory</font> review of     PolyHeme, it is possible that, before PolyHeme can be <font color="blue">commercialize</font>d, any     related  patent  may expire or remain in force for only a short period     following <font color="blue">commercialization</font>, thereby reducing any <font color="blue">advantages</font> of the patent</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">trade secrets</font></font> and other <font color="blue">confidential</font> information to maintain our     <font color="blue">proprietary</font> position</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">patent protection</font>, we <font color="blue">also rely on protection</font> of trade     secrets, know-how and <font color="blue">confidential</font> and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>To maintain     the <font color="blue">confidential</font>ity of <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> information, we have     entered into <font color="blue">confidential</font>ity <font color="blue">agreement</font>s with our employees, <font color="blue">consultants</font> and     <font color="blue"><font color="blue">collaborators</font> upon</font> the                                         21       _________________________________________________________________    [75]Table of <font color="blue">Contents       </font><font color="blue">commencement</font> of their <font color="blue">relationships with us</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s require that     all <font color="blue">confidential</font> information developed by the individual or made known to     the individual <font color="blue">by us during</font> the course of the individual’s relationship with     us be kept <font color="blue">confidential</font> and not disclosed to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">agreement</font>s     <font color="blue">with employees also provide</font> that <font color="blue">inventions</font> conceived by the individual in     the course of rendering services to us will be our <font color="blue">exclusive property</font></td>
    </tr>
    <tr>
      <td><font color="blue">Individuals </font>with whom we have these <font color="blue">agreement</font>s may not <font color="blue">comply with</font> their     terms</td>
    </tr>
    <tr>
      <td>In the event of the <font color="blue">unauthorized</font> use or <font color="blue">disclosure</font> of our trade     secrets or <font color="blue">proprietary</font> information, these <font color="blue">agreement</font>s, even if obtained, may     not  provide  <font color="blue">meaningful</font>  protection  for  our  <font color="blue">trade secrets</font> or other     <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>To the extent that our employees, <font color="blue">consultants</font> or     <font color="blue">contractors</font> use <font color="blue">technology</font> or know-how owned by others in their work for us,     disputes may arise as to the rights in related <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>remedies     may  not  exist  in the event of <font color="blue">unauthorized</font> use or <font color="blue">disclosure</font> of our     <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>The <font color="blue">disclosure</font> of our <font color="blue">trade secrets</font> would impair     our <font color="blue"><font color="blue">competitive</font> position</font> and could have a material adverse effect on our     operating results, <font color="blue">financial condition</font> and <font color="blue">future growth prospects</font></td>
    </tr>
    <tr>
      <td>We may be involved in lawsuits to protect or enforce our patents, which     could be expensive and time consuming</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may infringe our patents</td>
    </tr>
    <tr>
      <td>To <font color="blue">counter <font color="blue">infringement</font></font> or     <font color="blue">unauthorized</font> use, we may be required to <font color="blue">file <font color="blue">infringement</font></font> claims, which can     be expensive and time-consuming</td>
    </tr>
    <tr>
      <td>In addition, in an <font color="blue"><font color="blue">infringement</font> proceeding</font>,     a <font color="blue">court may decide</font> that a patent of ours is not valid or is unenforceable,     or may refuse to stop the other <font color="blue">party from using</font> the <font color="blue">technology</font> at issue on     the  grounds  that our patents do not cover its <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>An adverse     <font color="blue">determination</font> of any <font color="blue">litigation</font> or <font color="blue">defense <font color="blue">proceedings</font> <font color="blue">could put</font> one</font> or more     of our <font color="blue">patents at risk</font> of being invalidated or <font color="blue">interpreted narrowly</font> and     <font color="blue">could put</font> our patent <font color="blue">application</font>s at risk of not issuing</td>
    </tr>
    <tr>
      <td><font color="blue">Interference </font><font color="blue"><font color="blue">proceedings</font> brought by</font> the <font color="blue">United States</font> Patent and     <font color="blue">Trademark Office </font>may be <font color="blue">necessary</font> to determine the priority of <font color="blue">inventions</font>     <font color="blue">with respect</font> to our patent <font color="blue">application</font>s or those of our <font color="blue">collaborators</font> or     <font color="blue">licensors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>or interference <font color="blue">proceedings</font> may fail and, even if     successful, may result in substantial costs and be a <font color="blue">distraction</font> to our     <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>We  may  not  be  able to <font color="blue">prevent misappropriation</font> of our     <font color="blue">proprietary</font> rights, <font color="blue">particularly</font> in countries where the laws may not protect     <font color="blue">such rights as fully as</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Furthermore, because of the substantial amount of <font color="blue">discovery</font> required     in <font color="blue"><font color="blue">connection</font> with</font> <font color="blue">intellectual property</font> <font color="blue">litigation</font>, there is a risk that     some of our <font color="blue">confidential</font> information could be compromised by <font color="blue">disclosure</font>     during this type of <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>In addition, during the course of this kind     of  <font color="blue">litigation</font>,  <font color="blue">there could</font> be <font color="blue">public <font color="blue">announcements</font></font> of the results of     hearings,  motions  or  other  interim <font color="blue">proceedings</font> or <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>If     <font color="blue">securities analysts</font> or investors perceive these results to be negative, it     could have a substantial adverse effect on the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We may not prevail in any <font color="blue">litigation</font> or <font color="blue">interference proceeding</font> in     which we are involved</td>
    </tr>
    <tr>
      <td>Even if we do prevail, these <font color="blue">proceedings</font> can be very     expensive and distract our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> own or <font color="blue">control patents</font> or patent <font color="blue">application</font>s that are     <font color="blue">infringed by</font> our product or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part on avoiding the <font color="blue">infringement</font> of other     parties’  patents and <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, patent     <font color="blue">application</font>s filed in <font color="blue">recent years</font> are <font color="blue">confidential</font> for 18 months, while     older <font color="blue">application</font>s are not <font color="blue">published until</font> the <font color="blue">patent issues</font></td>
    </tr>
    <tr>
      <td>As a result,     there  may  be  patents  of  which we are unaware, and avoiding patent     <font color="blue">infringement</font> may be <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>We may inadvertently infringe third-party     patents or patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">third parties</font> could bring claims     <font color="blue">against us</font> that, even if resolved in our favor, could cause us to incur     substantial expenses and, if resolved <font color="blue">against us</font>, could <font color="blue">additional</font>ly cause     us to pay substantial damages</td>
    </tr>
    <tr>
      <td>Further, if a patent <font color="blue">infringement</font> suit were     brought  against  us,  we  could  be forced to stop or <font color="blue">delay research</font>,     <font color="blue">development</font>, <font color="blue">manufacturing</font> or sales <font color="blue">of PolyHeme </font>in the country or countries     <font color="blue">covered by</font> the patent we infringe, unless we can obtain a <font color="blue">license from</font> the     <font color="blue">patent holder</font></td>
    </tr>
    <tr>
      <td>Such a license may not be <font color="blue">available on</font> acceptable terms, or     at all, <font color="blue">particularly</font> if the third party is developing or marketing a product     <font color="blue"><font color="blue">competitive</font> with</font> PolyHeme</td>
    </tr>
    <tr>
      <td>Even if we were able to obtain a license, the     <font color="blue">rights may</font> be nonexclusive, which would give our <font color="blue"><font color="blue">competitors</font> access</font> to the     same <font color="blue">intellectual property</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [76]Table of <font color="blue">Contents       </font>      We also may be required to pay substantial damages to the patent     holder in the event of an <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Under some <font color="blue">circumstances</font> in the     <font color="blue">United States</font>, these <font color="blue">damages could</font> be triple the <font color="blue">actual damages</font> the patent     <font color="blue">holder incurs</font></td>
    </tr>
    <tr>
      <td>If we have <font color="blue">supplied infringing products</font> to <font color="blue">third parties</font> for     marketing or licensed <font color="blue">third parties</font> to <font color="blue">manufacture</font>, use or <font color="blue">market infringing</font>     products, we may be obligated to indemnify these <font color="blue">third parties</font> for any     damages they may be required to pay to the <font color="blue">patent holder</font> and for any losses     the <font color="blue">third parties</font> may sustain themselves as the result of lost sales or     <font color="blue">damages paid</font> to the <font color="blue">patent holder</font></td>
    </tr>
    <tr>
      <td>Any  successful <font color="blue">infringement</font> action brought <font color="blue">against us</font> may also     <font color="blue">adversely affect marketing</font> <font color="blue">of PolyHeme </font>in other markets not <font color="blue">covered by</font> the     <font color="blue">infringement</font> action</td>
    </tr>
    <tr>
      <td>Furthermore, we <font color="blue">may suffer adverse consequences from</font> a     successful <font color="blue">infringement</font> action <font color="blue">against us</font> even if the action is <font color="blue">subsequently</font>     reversed  on  appeal,  <font color="blue">nullified through</font> another action or <font color="blue">resolved by</font>     <font color="blue">settlement with</font> the <font color="blue">patent holder</font></td>
    </tr>
    <tr>
      <td>The damages or other <font color="blue">remedies awarded</font>, if     any, may be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>As a result, any <font color="blue">infringement</font> action <font color="blue">against us</font>     would likely delay the <font color="blue"><font color="blue">regulatory</font> approval</font> process, harm our <font color="blue">competitive</font>     position, be very costly and require <font color="blue">significant</font> time and attention of our     key <font color="blue">management</font> and technical personnel</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR COMMON STOCK       Our <font color="blue">stock price could</font> be volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has fluctuated <font color="blue">significant</font>ly in     response to a number of factors, many are which are beyond our control,     including:         •  <font color="blue">regulatory</font> <font color="blue">development</font>s relating to our PolyHeme product;         •  <font color="blue">announcements</font> by us relating to the results of our <font color="blue"><font color="blue">clinical trial</font>s</font> of     PolyHeme;         •  <font color="blue">development</font>s relating to our efforts to obtain <font color="blue">additional</font> financing to     fund our <font color="blue">operations</font>;         •  <font color="blue">announcements</font> by us regarding <font color="blue"><font color="blue">transactions</font> with potential strategic</font>     partners;         •  <font color="blue">announcements</font> relating to <font color="blue">blood substitute products</font> being developed by     our <font color="blue">competitors</font>;         •  changes in <font color="blue">industry trends</font> or <font color="blue">conditions</font>;         •  our issuance of <font color="blue">additional</font> equity or <font color="blue">debt securities</font>; and         •  sales of <font color="blue">significant</font> amounts of our <font color="blue">common stock</font> or other securities in     the market</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> in general, and the <font color="blue">Nasdaq Global Market     </font>and  the bio<font color="blue">technology</font> industry market in particular, have experienced     <font color="blue">significant</font> price and volume <font color="blue">fluctuations</font> that have often been unrelated or     <font color="blue">disproportionate</font> to the operating performance of <font color="blue">listed companies</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">broad market</font> and <font color="blue">industry factors may seriously harm</font> the <font color="blue">market price</font> of our     common  stock,  <font color="blue">regardless</font>  of our operating performance</td>
    </tr>
    <tr>
      <td>In the past,     securities class action <font color="blue">litigation</font> has often been instituted following     periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a company’s securities</td>
    </tr>
    <tr>
      <td>A     securities class action suit <font color="blue">against us</font> could result in substantial costs,     potential <font color="blue">liabilities</font> and the diversion of our <font color="blue">management</font>’s attention and     resources</td>
    </tr>
    <tr>
      <td>Anti-takeover  provisions  contained  in  our charter and <font color="blue">bylaws could</font>     <font color="blue">discourage potential takeover attempts</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of in<font color="blue">corporation</font> contains a “fair price” provision     which requires approval of the holders of at least 80prca of our <font color="blue">voting stock</font>,     excluding  shares  held  by  certain interested <font color="blue">stockholders</font> and their     affiliates, as a condition to mergers or certain other business <font color="blue">combinations</font>     with, or <font color="blue">proposed by</font>, any holder of 15prca or more of our <font color="blue">voting stock</font>, except     in  cases where approval of our disinterested <font color="blue">directors</font> is obtained or     certain  minimum  <font color="blue">price criteria</font> and other procedural <font color="blue"><font color="blue">requirement</font>s</font> are     satisfied</td>
    </tr>
    <tr>
      <td>In addition, our board of <font color="blue">directors</font> has the authority, without     <font color="blue">further action by</font> our <font color="blue">stockholders</font>, to fix the rights and <font color="blue">preferences</font> and     <font color="blue">issue shares</font> of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>These provisions, and other provisions of     our <font color="blue">certificate</font> of in<font color="blue">corporation</font> and bylaws and <font color="blue">Delaware </font>law, may have the     effect of <font color="blue">deterring hostile takeovers</font> or delaying or preventing changes in     our control or <font color="blue">management</font>, including <font color="blue">transactions</font> in which <font color="blue">stockholders</font>     <font color="blue">might otherwise</font> receive a premium for their <font color="blue">shares over</font> the <font color="blue">then prevailing</font>     <font color="blue">market price</font>s</td>
    </tr>
  </tbody>
</table>